Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 10, 2010 - Issue 12
Submit an article Journal homepage
90
Views
6
CrossRef citations to date
0
Altmetric
Theme: Bladder Cancer - Special Report

Prognostic value of CA 125 in transitional cell carcinoma of the bladder

Ankur M Manvar Division of Urologic Surgery, The University of North Carolina at Chapel Hill, 2140 Bioinformatics Building, CB #7235, Chapel Hill, NC 27599, USA; Division of Urologic Surgery, The University of North Carolina at Chapel Hill, 2140 Bioinformatics Building, CB #7235, Chapel Hill, NC 27599, USA
,
Eric M Wallen Division of Urologic Surgery, The University of North Carolina at Chapel Hill, 2140 Bioinformatics Building, CB #7235, Chapel Hill, NC 27599, USA; Division of Urologic Surgery, The University of North Carolina at Chapel Hill, 2140 Bioinformatics Building, CB #7235, Chapel Hill, NC 27599, USA
,
Raj S Pruthi Division of Urologic Surgery, The University of North Carolina at Chapel Hill, 2140 Bioinformatics Building, CB #7235, Chapel Hill, NC 27599, USA;[email protected]
&
Matthew E Nielsen Division of Urologic Surgery, The University of North Carolina at Chapel Hill, 2140 Bioinformatics Building, CB #7235, Chapel Hill, NC 27599, USA; Division of Urologic Surgery, The University of North Carolina at Chapel Hill, 2140 Bioinformatics Building, CB #7235, Chapel Hill, NC 27599, USA
Pages 1877-1881 | Published online: 10 Jan 2014

References

  • Margel D, Tal R, Baniel J. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer. J. Urol.178(6), 2297–2300 (2007).
  • Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J. Urol.163(6), 1693–1696 (2000).
  • Buy JN, Moss AA, Guinet C et al. MR staging of bladder carcinoma: correlation with pathologic findings. Radiology169(3), 695–700 (1988).
  • Shariat SF, Palapattu GS, Karakiewicz PI et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur. Urol.51(1), 137–151 (2007).
  • Cook AM, Huddart RA, Jay G, Norman A, Dearnaley DP, Horwich A. The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer. Br. J. Cancer82(12), 1952–1957 (2000).
  • Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem.276(29), 27371–27375 (2001).
  • Chang A, Cai J, Miranda G, Groshen S, Skinner D, Stein JP. Usefulness of CA 125 as a preoperative prognostic marker for transitional cell carcinoma of the bladder. J. Urol.172, 2182–2186 (2004).
  • Ammon A, Weber MH, Wallner I et al. Expression of the tumor-associated glycoproteins MCA, CA 125 and BW 495/36-P in epithelial tumors of the kidney and the urinary bladder. Int. J. Biol. Markers9(4), 224–230 (1994).
  • Berek JS, Bast RC Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer76, 2092–2096 (1995).
  • Bast RC Jr. Status of tumor markers in ovarian cancer screening. J. Clin. Oncol.21, 200–205 (2003).
  • Izes JK, Dyer MW, Callum MG, Bankes P, Libertino JA, Caffrey JA. CA 125 as a marker of tumor activity in advanced urothelial malignancy. J. Urol.165, 1908–1913 (2001).
  • Chung HH, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet. Gynecol. Scand.85(12), 1501–1505 (2006).
  • Chaube A, Tewari M, Singh U, Shukla HS. CA 125: a potential tumor marker for gallbladder cancer. J. Surg. Oncol.93(8), 665–669 (2006).
  • Kouba EJ, Lentz A, Wallen EM, Pruthi RS. Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urol. Oncol.27(5), 486–490 (2009).
  • van Ingen HE, Chan DW, Hubl W et al. Analytical and clinical evaluation of an electro-chemiluminescence immunoassay for the determination of CA 125. Clin. Chem.44(12), 2530–2536 (1998).
  • Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am. J. Clin. Pathol.117(3), 471–477 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.